Evidence map›Paper›PMID 26736179›Full record

ArticleMolecular medicine (Cambridge, Mass.)2016

ARA290 Improves Insulin Release and Glucose Tolerance in Type 2 Diabetic Goto-Kakizaki Rats.

Carole Muller, Kamal Yassin, Luo-Sheng Li, Magnus Palmblad, Suad Efendic, Per-Olof Berggren, Anthony Cerami, Michael Brines, Claes-Göran Östenson

Open access · goldAbstract read
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Carole MullerDept of Molecular Medicine and Surgery, Karolinska Institutet (KI), Stockholm, Sweden.
Kamal YassinDept of Molecular Medicine and Surgery, Karolinska Institutet (KI), Stockholm, Sweden.
Luo-Sheng LiDept of Molecular Medicine and Surgery, Karolinska Institutet (KI), Stockholm, Sweden.
Magnus PalmbladDept Vascular Surgery, Leiden University Medical Center, The Netherlands.
Suad EfendicDept of Molecular Medicine and Surgery, Karolinska Institutet (KI), Stockholm, Sweden.
Per-Olof BerggrenDept of Molecular Medicine and Surgery, Karolinska Institutet (KI), Stockholm, Sweden.
Anthony CeramiAraim Pharmaceuticals, Tarrytown, New York, United States of America.
Michael BrinesAraim Pharmaceuticals, Tarrytown, New York, United States of America.
Claes-Göran ÖstensonDept of Molecular Medicine and Surgery, Karolinska Institutet (KI), Stockholm, Sweden.
Araim Pharmaceuticals (United States) · USKarolinska Institutet · SEKarolinska University Hospital · SELeiden University Medical Center · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Effects of ARA290 on glucose homeostasis were studied in type 2 diabetic Goto-Kakizaki (GK) rats. In GK rats receiving ARA290 daily for up to 4 wks, plasma glucose concentrations were lower after 3 and 4 wks, and hemoglobin A1c (Hb A1c) was reduced by ~20% without changes in whole body and hepatic insulin sensitivity. Glucose-stimulated insulin secretion was increased in islets from ARA290-treated rats. Additionally, in response to glucose, carbachol and KCl, islet cytoplasmic free Ca

Identifiers

PMID26736179
PMCPMC4818260
OpenAlexW2471821142

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.